Arcutis Biotherapeutics Quarterly Cash Flow Statement
NASDAQ: ARQTHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Arcutis Biotherapeutics free cash flow
In the quarter ended Jun 30, 2026, Arcutis Biotherapeutics generated $12.6 million of operating cash flow and spent $158,000 on capital expenditures. That left free cash flow of $12.5 million, a free-cash-flow margin of 9.6% of revenue. Free cash flow was up 4973.6% from the prior year's $246,000.
Summary generated from market data by MetaCap's automated system. Methodology
Arcutis Biotherapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 15.01M | -11.29M | 17.39M | 7.41M | -15.89M | -25.06M | -10.79M | -41.54M | -52.33M | -35.38M | -66.28M | -44.77M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | — | — | — | — | — | 153.00K | 105.00K | 161.00K | 164.00K | 170.00K | 227.00K | 200.00K |
| Stock-Based Compensation | 12.76M | 10.69M | 10.06M | 10.04M | 10.49M | 9.78M | 9.39M | 9.78M | 12.52M | 10.03M | 8.76M | 10.00M |
| Change in Working Capital | -16.09M | 1.93M | -2.20M | -19.79M | 5.33M | -17.49M | -1.38M | -3.62M | -4.08M | -5.26M | 579.00K | -9.02M |
| Operating Cash Flow | 12.64M | 2.24M | 26.18M | -1.75M | 324.00K | -30.38M | -748.00K | -34.69M | -45.12M | -31.60M | -56.24M | -43.98M |
| Capital Expenditures | -158.00K | 0 | 0 | 0 | -78.00K | -608.00K | 0 | -143.00K | 0 | 0 | -6.00K | -64.00K |
| Investing Cash Flow | -15.22M | -11.33M | -34.18M | -25.25M | 17.42M | 11.75M | 34.88M | 84.78M | -62.14M | -28.70M | -62.19M | 45.55M |
| Debt Issued | — | — | — | — | — | — | — | — | — | — | 0 | — |
| Financing Cash Flow | 1.99M | 1.07M | 3.72M | 1.48M | 1.38M | 395.00K | -97.41M | 394.00K | 1.46M | 161.76M | 99.29M | 867.00K |
| Net Change in Cash | -641.00K | -8.14M | -4.21M | -25.62M | 19.33M | -18.23M | -63.52M | 50.58M | -105.83M | 101.39M | -19.07M | 2.36M |
| Free Cash Flow | 12.48M | 2.24M | 26.18M | -1.75M | 246.00K | -30.99M | -748.00K | -34.83M | -45.12M | -31.60M | -56.25M | -44.05M |
This table shows 12 quarterly periods of Arcutis Biotherapeutics's cash flow statement, from Q2 2026 back to Q3 2023, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow ARQT's reporting calendar. What is a cash flow statement?